DRG uses cookies to improve your experience on this website. Some of the cookies we use are essential for parts of the website to operate. Please be aware that if you continue without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.

Research & Reports

Searching in Biopharma (1951)

Dyslipidemia | Current Treatment | Detailed, Expanded Analysis (US) - Treatment Algorithms - Claims Data Analysis

Dyslipidemia | Current Treatment | Detailed, Expanded Analysis (US) - Treatment Algorithms - Claims Data Analysis

Thank you!

Your request has been received by DRG. A represantative will contact you shortly to provide more details on the research and data contained in this report and ensure that it will meet your current research needs.

Dyslipidemia is a key modifiable risk factor for cardiovascular (CV) disease. Current lipid-modifying therapies, including statins, ezetimibe, fibrates, omega-3 fatty acid compounds, and PCSK9 inhibitors, focus on improving lipid levels with an end goal to achieve CV risk reduction. Statins dominate the market owing to their good risk-benefit profile and evidence for reducing CV morbidity and mortality. With the positive outcomes data for certain nonstatin therapies such as PCSK9 inhibitors and Vascepa, treatment dynamics are evolving. Using a longitudinal claims data analysis, we demonstrate how dyslipidemia is treated in the United States in both newly diagnosed and recently treated patients.

QUESTIONS ANSWERED

  • What patient shares do key therapies and brands garner by line of therapy in newly diagnosed dyslipidemia patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed dyslipidemia patients?
  • How have PCSK9 inhibitors been integrated into the treatment algorithm?
  • What percentage of dyslipidemia patients receive drug therapy within one year of diagnosis, and how quickly do they receive it? What percentage of patients progress to later lines of therapy within one year of diagnosis?
  • What percentage of dyslipidemia patients are treated with monotherapy versus combination therapy? What are the most commonly used combinations?
  • What are the product-level compliance and persistency rates among drug-treated dyslipidemia patients?

PRODUCT DESCRIPTION

Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data, so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.

Table of contents

  • Detailed, Expanded Analysis (US) - Treatment Algorithms - Claims Data Analysis
    • Treatment Algorithm Dyslipidemia US May 2019

Already a Client? Log in to access this report.

  • Pub Date: May 2019
  • Author(s): Pallavi Malik, M.Sc
  • Pallavi Malik is a business insights analyst in the Cardiovascular, Metabolic and Renal disorders team at Decision Resources Group. She obtained an degree with specializations in Biotechnology, and a Bachelor's degree in Science from the Panjab University, Chandigarh, India. Prior to joining DRG, she has worked as a Senior Business Analyst at the research firm Evalueserve. Her role involved in-depth scientific secondary research, and competitive intelligence across multiple domains (such as oncology, ophthalmology and CVD) including pipeline analysis, clinical trials assessment, disease landscaping, product and company profiling, competitor benchmarking, and opportunity assessment.  

Purchase Report

Recent reports:
You may also be interested in: